AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04275219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tongfu capsules
Description: Tongfu capsules include 5 herbals
Study NCT04275219 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: The Placebo of Tongfu capsules
Description: The Placebo of Tongfu capsules are made from dextrin, starch and so on.
Study NCT01643083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin
Description: Rifaximin 400mg tid for 2 wk
Study NCT01643083 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 2 week
Study NCT03779399 — intervention group
Intervention type: OTHER
Intervention: Assessment of percentage of Treg, Th17, NKT and serum level of HE4, CA125 and ROMA.
Description: Treg, Th17, NKT cells in peripheral blood and ovarian tissue and serum level of HE4, CA125 and ROMA.
Study NCT02152787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of propofol 1.0mg/kg
Study NCT02152787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol 0.5mg/kg
Study NCT02152787 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Study NCT00670878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 x FEC 3 x DOC / Gemcitabine
Description: 3 cycles of 5-Fluorouracil 500 mg/m² i.v. body surface area and Epirubicin 100 mg/m² i.v. and Cyclophosphamide 500 mg/m² i.v., (FEC100), each administered on day 1, repeated on day 22, subsequently followed by 3 cycles of Docetaxel 75 mg/m² body surface area i.v. (D), and Gemcitabine 1000 mg/m² i.v. (30 min infusion) (G), administered on day 1, followed by Gemcitabine 1000 mg/m² i.v. (30 min infusion) on day 8, repeated on day 22
Study NCT00670878 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3 x FEC 3 x DOC
Description: 3 cycles of 5-Fluorouracil 500 mg/m² i.v. body surface area and Epirubicin 100 mg/m² i.v. and Cyclophosphamide 500 mg/m² i.v., (FEC100), each administered on day 1, repeated on day 22, subsequently followed by 3 cycles of Docetaxel 100 mg/m² body surface area i.v. (D), administered on day 1, repeated on day 22
Study NCT01428024 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Lip Volume
Description: Treatment of up to 1,5 ml product for upper and lower lip, respectively at week 0 and optional at week 12.
Study NCT01428024 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Lip Refresh
Description: Treatment of up to 0,5 ml product for upper and lower lip, respectively at week 0 and optional at week 12.
Study NCT04511351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: chidamide administration during radiation and chemotherapy phase in the study group
Study NCT02038634 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone
Study NCT04786431 — intervention group
Intervention type: OTHER
Intervention: Blood collection for lipid profiling by LC-MS
Description: Blood withdrawal
Study NCT02038634 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Ultrasound guided injection using GE Healthcare LOGIQ e Ultrasound
Study NCT02689895 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: modified directly administered anti-retroviral therapy (mDAART)
Description: As described before
Study NCT01017679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib 500mg/Gefitinib 250mg
Description: Gefitinib 500mg or 250mg is Taken Orally everyday by Experimental and controlled Arms respectively
Study NCT01017679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib 500mg/Gefitinib 250mg
Description: Gefitinib 500mg or 250mg is Taken Orally everyday by Experimental and controlled Arms respectively
Study NCT01252199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cαStx1/cαStx2
Description: cαStx1/cαStx2 administered concomitantly at a dose of 1 mg/kg (low dose cohort) or 3 mg/kg (high dose cohort)per antibody over 1 hour + standard of care
Study NCT01252199 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered over 1 hour + standard of care
Study NCT01854372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-HCVAD and R-MC
Study NCT00149071 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: 15 treatments of rTMS active with a duration of 30 minutes each
Study NCT01527539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Dose individually adjusted. Injected twice daily immediately before breakfast and dinner. Administrated subcutaneously (s.c., under the skin)
Study NCT04689958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: Gabapentin, pregabalin, or amitriptyline
Study NCT04689958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard therapy
Description: Gabapentin, pregabalin, or amitriptyline
Study NCT04689958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D 5,000IU Oral Tablet
Description: Vitamin D 5000 IU oral tablet once daily
Study NCT02265952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1500 250 mg SC/15 mg/kg IV/450 mg SC
Description: Participants received single dose of REGN1500 subcutaneous (SC) injection of 250 milligrams (mg) at Week 0 (Day 1), followed by single dose of REGN1500 intravenous (IV) injection of 15 milligrams per kilogram (mg/kg) at Week 2 (Day 15) and then followed by 4 doses of REGN1500 SC injection of 450 mg once weekly starting from Week 12 (Day 85). Only the first 2 enrolled participants received 4 weekly REGN1500 450 mg SC doses at weeks 12, 13, 14, and 15 per the protocol. This dose regimen was removed under protocol amendment 4. Participants were followed for a period of 24 weeks (through Week 26 \[Day 183\]) after the last dose of study drug in the main study period.
Study NCT03459326 — intervention group
Intervention type: OTHER
Intervention: IIEF (International Index of Erectile Function questionnaire )
Description: The questionnaire is presented and answered without help. Answers to the IIEF Questionnaire will be collected in order to obtain the following scores (the total score is of no interest):~* Erectile function (score 1 to 30)~* Orgasmic function (score 0 to 10)~* Desire (score 2 to 10)~* Sexual satisfaction (score 0 to 15)~* Overall satisfaction (score 2 to 10)
Study NCT02960074 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Capsule
Description: We will treat patients with oral encapsulated frozen FMT over 2 days.
Study NCT00326885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: catumaxomab
Description: Catumaxomab is administered intraperitoneally via an indwelling catheter (or port) as a 3-hour infusion 4 times (Days 0, 3, 7, and 10) in ascending doses (10 mcg, 20 mcg, 50 mcg, and 150 mcg, respectively).
Study NCT00460473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Study NCT06776107 — intervention group
Intervention type: OTHER
Intervention: Risk factor present
Description: Demographic, and severity.
Study NCT00460473 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01725113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: 3 times weekly
Study NCT01725113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcitriol
Description: 3 times weekly
Study NCT01725113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: 3 times weekly
Study NCT01725113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paricalcitol
Description: 3 times weekly
Study NCT01792856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recovery-oriented intervention
Description: Life coaching is defined as a collaborative, solution-focused, outcome-oriented and systematic process which aims to facilitate enhancement of life experience and goal attainment of an individual in various life domains. It is based on the theoretical framework of positive psychology and behavioural change model, and targets at building up an individual's potential via fostering hope, motivation, self-efficacy and self-regulation. The principles of life coaching thus closely align with recovery orientation that emphasizes on self-initiation and empowerment via person-centred and strength-based approach.
Study NCT01792856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psychoeducation
Description: Subjects will receive group-based supportive therapy provided by case managers of JCEP project. The therapy provides patients with psychoeducation about psychosis, stress management, emotional and social support. Coaching and cognitive-behavioural techniques will not be incorporated. Therapy sessions and duration will be comparable to that of recovery-oriented coaching program.
Study NCT02967198 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT/US fusion
Description: Fusion of pre-procedure cross-sectional imaging (CT or MRI) and real-time USG using registration function of USG device.
Study NCT02967198 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound shear wave elastography
Description: ultrasound shear wave elastography is performed in S-shear wave scanner according to guidelines of ultrasound elastography.
Study NCT01857791 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multidisciplinary, behavior modification
Study NCT02345486 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% sodium chloride
Study NCT02345486 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiologically balanced fluid
Study NCT00557973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XP19986 SR1, 10 mg BID
Description: XP19986 Sustained Release (SR) 10 mg tablet dosed orally, twice a day (BID), for approximately 26 days with titration and taper periods
Study NCT00557973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XP19986 SR1, 20 mg BID
Description: XP19986 Sustained Release (SR) 20 mg tablet dosed orally, twice a day (BID), for approximately 26 days with titration and taper periods
Study NCT00557973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XP19986 SR1, 30 mg BID
Description: XP19986 Sustained Release (SR) 30 mg tablet dosed orally, twice a day (BID), for approximately 26 days with titration and taper periods
Study NCT00557973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets to match active intervention, taken twice a day (BID) for approximately 26 days with titration and taper periods. Also taken during placebo washout periods.
Study NCT03989960 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LISA+SNIPPV
Description: The LISA+SNIPPV group receives PS by the way of invasive surfactant administration technique and selects nasal synchronized intermittent positive pressure ventilation.
Study NCT03989960 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional InSurE
Description: The traditional InSurE group receives intubation-surfactant- extubation technique and selects CPAP ventilation.
Study NCT03552120 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MORE
Description: MORE is a manualized integrative treatment strategy that targets transdiagnostic mechanisms in stress-related conditions. MORE is made up of three primary components: mindfulness training, cognitive restructuring, and savoring. Mindfulness training aims to increase attentional control to reduce cognitive bias toward negative information. Cognitive reappraisal promotes restructuring of maladaptive cognitions, which would otherwise intensify negative emotion and addictive behavior. Finally, MORE promotes savoring - mindful attention to and appreciation of pleasant events in life as a means of increasing positive emotion regulation.
Study NCT03552120 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Psychotherapy
Description: Supportive psychotherapy is a form of non-directive talk therapy, which follows a Rogerian person-centered approach. The therapist's primary objectives during a session will be (1) to communicate unconditional positive regard for the participant, (2) to communicate engagement and empathic understanding, and (3) to mirror a participant's affect.
Study NCT03717285 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Insert the UAS under direct vision
Description: Patients in this group，we use rigid ureteroscopy to insert the UAS under direct vision.
Study NCT03717285 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Insert the UAS under non direct vision
Description: Patients in this group，we insert the UAS by the experience of the surgeon and under non direct vision .
Study NCT01752920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Derazantinib low dose range
Description: Derazantinib was administered orally at dose levels from 25 mg QOD - 200 mg QD on a 28-day schedule.
Study NCT01752920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Derazantinib middle dose range
Description: Derazantinib was administered orally at dose levels from 250 mg QD - 325 mg QD on a 28-day schedule.
Study NCT01752920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Derazantinib high dose range
Description: Derazantinib was administered orally at dose levels from 400 mg QD - 425 mg QD on a 28-day schedule.
Study NCT01752920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Derazantinib at recommended phase 2 dose (RP2D)
Description: Derazantinib was administered orally at the recommended phase 2 dose of 300 mg QD on a 28-day schedule.
Study NCT03096613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Description: Levothyroxine is used to normalize the thyroid hormone level of patients allocated to levothyroxine.
Study NCT01362114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIHOGAYONGGOLMORYU TANG EXTRACT GRAN
Description: three times a day, AC 30 min., 4 capsules taken each time (4capsules=2.5g), 8 weeks
Study NCT01362114 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: three times a day, AC 30 min., 4 capsules taken each time (4capsules=2.5g), 8 weeks.
Study NCT03139747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib is an anti-cancer drug for the treatment of certain kinds of thyroid cancer, and potentially for other cancers as well. It was developed by Eisai Co. and acts as a multiple kinase inhibitor against the VEGFR1, VEGFR2 and VEGFR3 kinases.
Study NCT03139747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: It is currently used as an immunosuppressant to prevent rejection of organ transplants and in the treatment of renal cell cancer and other tumours. Much research has also been conducted on everolimus and other mTOR inhibitors as targeted therapy for use in a number of cancers.
Study NCT03082391 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heavy weight Mesh
Description: Patients will undergo ventral hernia repair with heavy weight mesh.
Study NCT03082391 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medium weight Mesh
Description: Patients will undergo ventral hernia repair with medium weight mesh.
Study NCT00861237 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nux vomica (active comparator)
Description: Patients receive Nux vomica in a homeopathic potentiation
Study NCT00861237 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (placebo comparator)
Description: Patients receive Placebo looking similar to active drug
Study NCT01470794 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Toca 511 vector
Description: All patients will receive Toca 511, a retroviral replicating vector that expresses the cytosine deaminase (CD) gene. CD converts the antifungal 5-FC to the anti-cancer drug 5-FU in cells that have been infected by the Toca 511 vector. Beginning approximately 6 weeks after administration of Toca 511, patients will begin courses of oral Toca FC at pre-specified intervals, depending on cohort, during the approximately 30 week study.
Study NCT01470794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toca FC
Study NCT00548353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK3207
Description: M3207 (20 mg); patients will be administered a single dose of 100 mg of MK3207 (i.e., 5 x20-mg tablets).
Study NCT00548353 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo (unspecified)
Description: M3207 (20 mg) Pbo; patients will be administered a single dose of 100 mg of MK3207 Pbo (i.e., 5 x20-mg tablets).
Study NCT04460352 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Neoadjuvant radiotherapy (arm A)
Description: 1.8 Gy fractions 5 days per week in 23 fractions to a total dose of 41.4 Gy.
Study NCT04460352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin, paclitaxel
Description: Carboplatin AUC 2 + Paclitaxel 50mg/m2 weekly x 5 (day 1, 8, 15, 22, 29), starting same day as radiotherapy
Study NCT04460352 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Esophagectomy
Description: Esophagectomy performed within 8 weeks after termination of chemoradiotherapy
Study NCT04460352 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiotherapy (arm B)
Description: Two alternative schemes:~1. 1.8 Gy fractions five days per week in 28 fractions to a total dose of 50.4 Gy.~2. 2.0 Gy fractions five days per week in 25 fractions to a total dose of 50 Gy.
Study NCT04460352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin, paclitaxel
Description: Carboplatin AUC 2 + Paclitaxel 50mg/m2 on day 1 weekly during the full course of radiotherapy (5 weeks or 6 weeks, depending on the radiotherapy regimen used).
Study NCT04460352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin, paclitaxel
Description: Cisplatin 75mg/m2 on the first day of weeks 1 and 5 + 5-fluorouracil 1000 mg/m2/day by continuous infusion on the first four days of weeks 1 and 5.
Study NCT04460352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin, calcium folinate, 5-fluorouracil
Description: FOLFOX: Oxaliplatin 85 mg/m2, calcium folinate 200 mg/m2 and 5-fluorouracil 400 mg/m2 on the first days of weeks 1, 3 and 5 + 5-fluorouracil 800 mg/m2 by continuous infusion on the first two days of weeks 1, 3 and 5.
Study NCT04460352 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagectomy
Description: Esophagectomy only in case of residual or recurrent locoregional cancer.
Study NCT04427696 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic walking intervention
Description: Walking exercise is self-controlled and tracked by daily dairy. All of the participants are obligated to record the start and end time of walking every day. And pedometers will be used for tracking walking steps including heart rate and calories. We plan to use pedometer in our study, which was reported the most accurate pedometer and suitable for scientific research. For the ones who are in the control group, they have to keep sedentary lifestyle, and no regular walking exercise, and they are agree to be in the comparable members in our study.
Study NCT04427696 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Aerobic walking intervention
Description: Walking exercise is self-controlled and tracked by daily dairy. All of the participants are obligated to record the start and end time of walking every day. And pedometers will be used for tracking walking steps including heart rate and calories. We plan to use pedometer in our study, which was reported the most accurate pedometer and suitable for scientific research. For the ones who are in the control group, they have to keep sedentary lifestyle, and no regular walking exercise, and they are agree to be in the comparable members in our study.
Study NCT00860106 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ED, DDimers and phone follow up
Description: ED score, DDimers level and phone questionnary
Study NCT00541281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: 35mg/m² on day 2 and 9 (21days in a cycle)
Study NCT00541281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: estramustine
Description: 140mg caps x3 bid from day 1to 5 and day 8 to 12 of each cycle
Study NCT00541281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: 2x5 mg a day
Study NCT04504864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low-dose aspirin
Description: 50mg aspirin is used to prevent recurrent stroke.
Study NCT04504864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional-does aspirin
Description: 100mg aspirin is used to prevent recurrent stroke.
Study NCT03979677 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Modifications
Description: Written suggestions on common migraine triggering food/beverages to avoid, restful sleep tips, exercise suggestions, and eating set mealtimes will be provided as the intervention.
Study NCT00653497 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aquatic exercise
Description: Arthritis Foundation Aquatics Program~* community-based aquatic exercise program~* participants asked to attend 2 classes per week for 20 weeks~* each class 45-60 minutes in duration
Study NCT01077713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 7.5mg/kg iv on day 1 of each 3 week cycle